Navigation Links
Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
Date:4/20/2009

antisense technology and adds to our previously published work using antisense to target different classes of RNAs, including microRNAs and other non-coding RNAs. We and our collaborators have shown that antisense inhibition of non-coding RNAs can impact splicing patterns in cells to modulate the expression of multiple proteins that may be involved in disease," said C. Frank Bennett, Ph.D., Senior Vice President of Research at Isis Pharmaceuticals. "Furthermore, the work of our team on STAT5 provides yet another oncology target with the potential for anti-tumor activity. We believe that antisense drugs have pharmaceutical properties that make them attractive therapeutics for cancer, and we are expanding our efforts in cancer to include new targets and new approaches."

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery an
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brazils top automakers to distribute 2 million copies of the Ethanol Handbook in partnership with the Brazilian Sugarcane Industry Association
2. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
3. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
4. US Oncology Clinical Development Attends Partnerships With CROs
5. Aviation partners to cut 500,000 tonnes of CO2 a year
6. ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions
7. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
8. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
10. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
11. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... Lancée par l,Assistance ... en décembre 2011, l,étude collaborative française randomisée ... compare   l es microsphères en résine ... le carcinome hépatocellulaire avancé, a recruté plus de ...   ; les résultats sont attendus fin 2016. ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... THE WOODLANDS, Texas, June 17 ... an Orphan Product Development Grant by the FDA,to support ... Pediatric Ventricular Assist Device (VAD). Dr. Christopher Almond of,the ... of,Clinical Affairs for Berlin Heart Inc. will serve as ...
... for liquid culture tests will accelerate access to improved ... BD (Becton, Dickinson and Company; NYSE: BDX ... (Foundation for Innovative New Diagnostics), a Swiss foundation that ... tools for poverty-related diseases, today announced a significant price ...
... OSLO, Norway, June 17 , ... to Improve Remission Rates and,Reduce Short-Term Mortality Compared to ... ASA (OSE: CLAVIS) today announces positive final results,from a ... elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia (AML). ...
Cached Biology Technology:Berlin Heart Inc. Receives FDA Orphan Product Development Grant 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... rate of incidence and mortality-the number of those who get ... Multiforme (GBM) is a brain cancer death sentence. , Of ... in the U.S., half will die within a year, and ... stretch survival limits are exceptionally invasive surgeries to remove the ...
... vessels within the tissue of previously engineered heart muscle. ... function. The study is published in the journal ... individuals globally and contributing to increasing mortality rates, there ... One of the specific challenges in the field ...
... whales emit their characteristic calls remains largely a ... sounds provides a valuable way to track the ... devices equipped with hydrophones (underwater microphones), deployed in ... recent years to track seasonal occurrences of blue, ...
Cached Biology News:Radiotherapy advance points way to noninvasive brain cancer treatment 2Radiotherapy advance points way to noninvasive brain cancer treatment 3Underwater listening devices yield discoveries about endangered large whales 2
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products: